鱼类肠道微生物与宿主免疫系统相互作用研究进展

鱼类肠道中存在大量微生物,对于维持宿主健康具有重要作用。鱼类免疫系统能够监视并调控肠道微生物组成,维持肠道菌群稳态。同时,鱼类肠道共生微生物调节鱼类免疫系统,抑制病原微生物的过度增殖,保证宿主的健康。本文回顾了鱼类肠道微生物与宿主免疫系统相互作用的研究进展,重点介绍了宿主免疫系统识别肠道微生物、塑造肠道菌群以及益生菌对宿主免疫和肠道菌群的调控等,提出了理想的益生菌应该来自动物自身胃肠道,生产中应谨慎选用非宿主来源的益生菌,以期为推动鱼类肠道功能微生物开发和应用提供理论支撑。     

儿童重症手足口病肠道菌群和肠道黏膜通透性的研究进展

手足口病是由肠道病毒引起的儿童常见的传染病,有研究显示肠道病毒进人消化道后在肠黏膜内复制繁殖并持续释放到血液而发病,肠道黏膜是病毒人侵和增殖的主要场所。肠道菌群能防御感染和增强肠道屏障功能,肠道屏障功能在防御外源性和内源性感染方面发挥重要作用,同时在维持肠道免疫稳定和平衡方面也有重要的作用。益生菌是指数量适当时对宿主健康有利的活微生物,有研究报道益生菌在辅助治疗手足口病上是有效的。开展这方面的研究,对于探索手足口病的发病机制和益生菌防治手足口病有十分重要的意义。     

肠道黏膜免疫与炎症小体的研究进展

肠道是机体消化器官,为机体生命活动提供所需要的营养。肠道免疫系统有独特的功能,在抵抗潜在病原体侵入机体过程中发挥至关重要的作用。炎症小体是机体天然免疫系统中重要的蛋白复合体感受器,参与病原体引起的宿主防御反应,并在维持肠道免疫稳态中发挥关键作用。本文综述了肠道黏膜免疫系统及炎症小体在肠道免疫中的作用。     

肠道菌群与肿瘤化疗之间的互作关系

化疗药物的应用是当今治疗恶性肿瘤的主要方法之一。近年来,随着对人体微生物研究的不断深入,肠道菌群在疾病的诊断和治疗中发挥越来越重要的作用。肠道菌群具有调节炎症反应、维持肠道屏障功能稳定和调节免疫反应的作用,其菌株可能作为一种潜在的肿瘤诊断标志物。肠道菌群与化疗药物之间的关系越发紧密,如肠道菌群如何影响化疗药物的作用效果,恶心、呕吐、便秘、骨髓抑制等化疗药物的毒副作用对肠道菌群又有何种影响,应用益生菌后肠道菌群如何变化以及对化疗药物毒副作用有何影响。因此,本文回顾了化疗药物与肠道菌群相互作用研究的进展,希望为国内学者提供肠道菌群和癌症化疗之间关系的理论基础,并为治疗癌症提供新的研究思路。     

肠道菌群：肠道干细胞增殖分化的调节者

肠道干细胞(intestinal stem cells, ISCs)是肠道各类上皮细胞的来源,通过平衡增殖与分化维持肠道稳态。同时,肠道菌群及其代谢物在维持宿主肠道稳态中也发挥着重要作用。随着技术的发展,研究者认识到ISCs与肠道菌群之间存在相互作用。研究表明,ISCs对上皮细胞亚型的调控影响肠道菌群的组成,并且肠道菌群及其代谢物也影响ISCs介导的上皮发育。本文阐述了ISCs分化对肠道菌群的影响,重点总结了肠道菌群及其代谢物调控ISCs增殖分化的研究进展,从菌群调控ISCs的角度探讨肠道损伤的治疗思路,并对未来可能的研究方向进行讨论。     

白细胞介素-10在维持肠道稳态中的作用研究进展

肠道稳态是宿主肠道黏膜和免疫屏障、肠道环境、营养物质和代谢产物等相互作用而形成的动态平衡状态。白细胞介素-10(interleukin-10, IL-10)是IL-10细胞因子家族的成员之一,是免疫反应中重要的抗炎细胞因子,在维持肠道稳态中发挥重要作用。该文从IL-10在维持肠上皮细胞稳态、肠屏障完整性、肠道菌群平衡以及在肠道中的抗炎作用四个方面对IL-10在维持肠道稳态中作用的研究进展作一综述,并对IL-10在肠道疾病中的治疗前景进行展望。     

乳脂球膜对肠道健康作用的研究进展

目的：综述乳脂球膜（MFGM）调节肠道健康的研究进展,并对未来的研究方向进行展望。方法：总结有关MFGM与肠道健康的研究性论文、综述及书籍等。结果：MFGM可保护并促进肠道益生菌生长,调节肠道屏障及肠道炎症的相关蛋白表达。结论：MFGM具有调节肠道微环境、增强肠道屏障功能和改善肠道炎症等有益功能。     

炎症性肠病与肠道微生态的研究进展

炎症性肠病(inflammatoryboweldisease,IBD)是一种肠道慢性炎症性疾病,其发病机制尚不清楚。然而,IBD的发病率不断上升给患者及其家属带来了巨大的经济负担,需要找到积极有效的治疗方法来帮助患者。最新的观点认为,宿主和肠道微生物之间的平衡被打破会触发遗传易感个体的免疫炎症反应。肠道菌群失调在炎症性肠病的发病及发展过程中起着重要的作用。临床研究发现,IBD患者肠道菌群失调程度不同,而联合应用益生菌可以改善这些患者的症状。越来越多的研究者密切关注肠道菌群与IBD的关系,并进行了深入的基础和临床研究。本文从肠道菌群对IBD的生理影响以及益生菌和粪便细菌移植等方面进行综述。     

NLRP3炎症体与肠道疾病

Nod样受体蛋白3(Nod-like receptor protein 3,NLRP3)炎症体是机体先天免疫的重要感受器,通过诱导炎症反应和细胞焦亡参与宿主免疫防御,并在维持肠道稳态方面发挥重要作用。近年来,NLRP3炎症体在放射性肠炎、炎症性肠病、结直肠癌和其他肠道疾病中的作用引起临床医生与科研人员的广泛关注。本文就NLRP3炎症体的激活机制和其在肠道疾病中的作用机制进行综述,旨在为临床治疗提供新的靶点与思路。     

miRNAs对动物肠道健康的调控作用

miRNAs(micro RNAs)是一类长约22 nt,参与mRNA转录后调控的非编码小分子RNA。作为基因表达的关键调控因子,其参与了各类细胞的增殖、分化、凋亡以及机体的生长发育等多种生命活动。肠道不仅是机体营养物质消化吸收的主要部位,也是重要的免疫器官。研究表明,miRNAs在肠道中的表达丰富,对肠道正常的发育及功能起重要的调控作用。文章结合本研究组的研究成果,对miRNAs的生物合成以及其对动物肠道功能的影响、肠道稳态的维持等方面的研究进展做简要综述,以期在分子营养学方面,为深入了解miRNAs对动物肠道健康的调控作用提供理论指导依据。     

Neurobiology of pain

The neurobiology of pain had a notable interest in research focused on the study of neuronal plasticity development, nociceptors, molecular identity, signaling mechanism, ionic channels involved in the generation, modulation and propagation of action potential in all type of excitable cells. All the findings open the possibility for developing new therapeutic treatment. Nociceptive/inflammatory pain and neuropathic pain represent two different kinds of persistent chronic pain. We have reviewed the different mechanism suggested for the maintenance of pain, like descending nociceptive mechanism and their changes after tissue damage, including suppression and facilitation of defence behavior during pain. The role of these changes in inducing NMDA and AMPA receptors gene expression, after prolonged inflammation is emphasized by several authors. Furthermore, a relation between a persistent pain and amygdale has been shown. Molecular biology is the new frontier in the study of neurobiology of pain. Since the entire genome has been studied, we will able to find new genes involved in specific condition such as pain, because an altered gene expression can regulate neuronal activity after inflammation or tissue damage.     

Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms

Nonalcoholic fatty liver disease (NAFLD) is currently the most common liver disease worldwide, both in adults and in children. NAFLD is characterized by aberrant lipid storage in hepatocytes (hepatic steatosis) and inflammatory progression to nonalcoholic steatohepatitis. Evidences so far suggest that intrahepatic lipid accumulation does not always derive from obesity. Gut microbiota has been considered as a regulator of energy homeostasis and ectopic fat deposition, suggesting its implications in metabolic diseases. Probiotics are live microbial that alter the enteric microflora and have beneficial effects on human health. Although the molecular mechanisms of probiotics have not been completely elucidated yet, many of their effects have proved to be beneficial in NAFLD, including the modulation of the intestinal microbiota, an antibacterial substance production, an improved epithelial barrier function and a reduced intestinal inflammation. Given the close anatomical and functional correlation between the bowel and the liver, and the immunoregulatory effects elicited by probiotics, the aim of this review is to summarize today's knowledge about probiotics in NAFLD, focusing in particular on their molecular and biochemical mechanisms, as well as highlighting their efficacy as an emerging therapeutic strategy to treat this condition.     

人体肠道乳杆菌的最新研究进展

乳杆菌是健康人体肠道的重要菌群之一,它与肠道微生态系统的调节和代谢、免疫的调控密切相关。大多数乳杆菌对人类健康有积极作用,其中一部分已被归为益生菌。一直以来,乳杆菌在人体中的存在状态和作用机制都是肠道微生态领域的研究重点。本文总结了人体肠道乳杆菌在种类、数量和功能方面的最新进展,值得注意的是,基于现代分子生物学技术的研究发现乳杆菌在人体肠道菌群中所占的数量比例相当小。虽然在数量上不占优势,但在对宿主生理功能的影响和代谢过程的调节上有不可替代的作用。此外本文还讨论了该领域仍需研究的内容,为人们进一步探索提供一些帮助。     

基于肠道微生态改善的益生菌抗糖尿病作用机制研究进展

2型糖尿病(type 2 diabetes, T2D)会引起糖脂代谢紊乱,严重危害人类健康,为了防治这一流行病,急需寻找安全和无副作用的抗糖尿病的方法,其中,基于微生物方法治疗T2D最常见的策略是补充益生菌,其可通过对不同组织和代谢通路的调节来实现抗糖尿病的功效。益生菌摄入可通过降低慢性低度炎症,减少氧化应激,调节肠道菌群,增加短链脂肪酸含量来达到调控血糖的目的;通过增加胆固醇与胆盐的共沉淀作用,胆固醇在胃肠道内转化为粪甾醇,降低肝脏中3-羟基-3-甲基戊二酸单酰辅酶A还原酶活性,降低胆固醇转运体的表达及对脂肪细胞的调节来达到降脂的目的。本综述系统总结了益生菌抗糖尿病现状和基于肠道微生态的抗糖尿病分子机制,以期为益生菌作为降糖降脂等保健产品的开发利用提供理论依据。     

Adrenomedullin treatment reduces intestinal inflammation and maintains epithelial barrier function in mice administered dextran sulphate sodium

Hyperactivation and hyperpermeability of the intestinal epithelium is a hallmark of IBD. AM has been shown to reduce the severity of colitis in the acetic acid and TNBS-induced colitis model, however the mechanism of the therapeutic effect of AM against the colitis has not been clarified. Here, we show that the protective capability of AM is associated with suppression of inflammation and maintenance of the intestinal epithelial barrier function. In the DSS-induced colitis model, intra-rectal AM-treated mice showed a reduction in loss of body weight and severity of colitis. AM-treatment suppressed phosphorylation of STAT1 and STAT3 in the colonic epithelium, and altered the cytokine balance in the intestinal T cells, with lower levels of IFN-γ and TNF-α but higher levels of TGF-β. Expression of the epithelial intercellular junctions such as tight and adherence junctions were sustained in the AM-treated mice. In contrast, the epithelial junctions were down-regulated in the control mice, leading to loss of epithelial barrier integrity and enhanced permeability. Collectively, these data indicate a broad spectrum of AM-induced effects with respect to protection against DSS-induced colitis, and suggest a potential therapeutic value of this treatment for IBD.     

A potential role of probiotics in colorectal cancer prevention: review of possible mechanisms of action

A number of investigations, mainly using in vitro and animal models, have demonstrated a wide range of possible mechanisms, by which probiotics may play a role in colorectal cancer (CRC) prevention. In this context, the most well studied probiotics are certain strains from the genera of lactobacilli and bifidobacteria. The reported anti-CRC mechanisms of probiotics encompass intraluminal, systemic, and direct effects on intestinal mucosa. Intraluminal effects detailed in this review include competitive exclusion of pathogenic intestinal flora, alteration of intestinal microflora enzyme activity, reduction of carcinogenic secondary bile acids, binding of carcinogens and mutagens, and increasing short chain fatty acids production. Reduction of DNA damage and suppression of aberrant crypt foci formation have been well demonstrated as direct anti-CRC effects of probiotics on intestinal mucosa. Existing evidence clearly support a multifaceted immunomodulatory role of probiotics in CRC, particularly its ability to modulate intestinal inflammation, a well known risk factor for CRC. The effectiveness of probiotics in CRC prevention is dependent on the strain of the microorganism, while viability may not be a prerequisite for certain probiotic anticancer mechanisms, as indicated by several studies. Emerging data suggest synbiotic as a more effective approach than either prebiotics or probiotics alone. More in vivo especially human studies are warranted to further elucidate and confirm the potential role of probiotics (viable and non-viable), prebiotics and synbiotics in CRC chemoprevention.     

Molecular interactions between bacteria, the epithelium, and the mucosal immune system in the intestinal tract: implications for chronic inflammation

In the last few years, advances in immunology, metabolomics and microbial ecology have shown that the contribution of the intestinal microbiota to the overall health status of the host has been so far underestimated. In this context, intestinal epithelial cells play a crucial role in the maintenance of intestinal homoeostasis. Indeed, at the interface between the luminal content and host tissues, the intestinal epithelium must integrate pro- and anti-inflammatory signals to regulate innate and adaptative immune responses, i.e. to control inflammation. However, under the influence of environmental factors, disturbance of the dialog between enteric bacteria and epithelial cells contributes to the development of chronic inflammation in genetically susceptible hosts. The present review covers the state of knowledge of the host response, especially in intestinal epithelial cells, to enteric bacteria, including colitogenic and probiotic bacteria. It also seeks to give an overview of potential regulatory mechanisms involved in the maintenance of intestinal homeostasis, and discusses the clinical implications for inflammatory bowel diseases.     

固有淋巴细胞在脂质代谢中的研究进展

由于世界范围内营养条件和生活方式的变化,肥胖及其相关的代谢性疾病已成为当前威胁人类健康的重要因素之一.在能量摄取和消耗以及体内脂肪储存、分解和脂肪组织重塑的研究中,人们逐渐认识到脂质过量及异位堆积将导致代谢组织处于慢性炎症状态,这开启了肥胖相关组织炎症研究的新方向.固有淋巴细胞(innate lymphoid cell...     

Gut dysbacteriosis and intestinal disease: mechanism and treatment

The gut microbiome functions like an endocrine organ, generating bioactive metabolites, enzymes or small molecules that can impact host physiology. Gut dysbacteriosis is associated with many intestinal diseases including (but not limited to) inflammatory bowel disease, primary sclerosing cholangitis-IBD, irritable bowel syndrome, chronic constipation, osmotic diarrhoea and colorectal cancer. The potential pathogenic mechanism of gut dysbacteriosis associated with intestinal diseases includes the alteration of composition of gut microbiota as well as the gut microbiota–derived signalling molecules. The many correlations between the latter and the susceptibility for intestinal diseases has placed a spotlight on the gut microbiome as a potential novel target for therapeutics. Currently, faecal microbial transplantation, dietary interventions, use of probiotics, prebiotics and drugs are the major therapeutic tools utilized to impact dysbacteriosis and associated intestinal diseases. In this review, we systematically summarized the role of intestinal microbiome in the occurrence and development of intestinal diseases. The potential mechanism of the complex interplay between gut dysbacteriosis and intestinal diseases, and the treatment methods are also highlighted.